Asset profile
Zanzalintinib
Small molecule
Phase 3underway
Evidence outlook · registrational
Colorectal Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2030-04-05.
Also in development:Non-Small Cell Lung Cancer · Phase 2Clear Cell Renal Cell Carcinoma · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
69 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 69 same-indication; 60 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Zanzalintinib: this drug | Phase 3 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Cabozantinib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK |
…and 54 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(44 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
December 2026 (3)
Phase 2Metastatic Castration-resistant Prostate CancerRecruiting
Est. primary completion 2026-12 · NCT06568562 · CT.gov ↗
What to watch
Phase 3Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-15 · NCT05678673 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06698250 · CT.gov ↗
What to watch
2027 (6)
January 2027 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-31 · NCT05176483 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive TumorRecruiting
Est. primary completion 2027-05-31 · NCT06952010 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Advanced Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-06 · NCT07185945 · CT.gov ↗
What to watch
Phase 1Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous Cell Carcinoma …Recruiting
Est. primary completion 2027-06-05 · NCT06912087 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8 …Not yet recruiting
Est. primary completion 2027-08-01 · NCT07511504 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06863311 · CT.gov ↗
What to watch
2028 (18)
February 2028 (2)
March 2028 (2)
May 2028 (1)
Phase 2Oral Cavity Squamous Cell Carcinoma, Head and Neck CancerNot yet recruiting
Est. primary completion 2028-05 · NCT07484139 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2Locally Advanced Renal Cell CarcinomaRecruiting
Est. primary completion 2028-06-06 · NCT06794229 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-06-15 · NCT07845786 · CT.gov ↗
What to watch
Phase 2Clear Cell Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-06-24 · NCT07578025 · CT.gov ↗
What to watch
July 2028 (4)
Phase 2Aggressive Variant Prostate CarcinomaRecruiting
Est. primary completion 2028-07 · NCT07218666 · CT.gov ↗
What to watch
Phase 2Metastatic Olfactory NeuroblastomaNot yet recruiting
Est. primary completion 2028-07-01 · NCT07527169 · CT.gov ↗
What to watch
Phase 2Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Bone Sarcoma, Translocation-associated Soft Tissue Sarcoma, Synovial Sarcomas …Recruiting
Est. primary completion 2028-07-01 · NCT06571734 · CT.gov ↗
What to watch
Phase 1Cancer, Pediatric CancerNot yet recruiting
Est. primary completion 2028-07-31 · NCT07773454 · CT.gov ↗
What to watch
August 2028 (2)
September 2028 (2)
Phase 2mCRPC (Metastatic Castration-resistant Prostate Cancer)Not yet recruiting
Est. primary completion 2028-09 · NCT07623460 · CT.gov ↗
What to watch
Phase 2Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma …Recruiting
Est. primary completion 2028-09-11 · NCT06959641 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Clear Cell Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-10-31 · NCT07691476 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic, Soft-Tissue SarcomaRecruiting
Est. primary completion 2028-11-01 · NCT07283731 · CT.gov ↗
What to watch
2029 (7)
March 2029 (1)
Phase 1/2Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8Recruiting
Est. primary completion 2029-03-04 · NCT07042919 · CT.gov ↗
What to watch
April 2029 (2)
May 2029 (1)
Phase 2Metastatic Castration-resistant Prostate CancerNot yet recruiting
Est. primary completion 2029-05 · NCT07608718 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2/3Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)Recruiting
Est. primary completion 2029-06-30 · NCT06943755 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Bone SarcomasRecruiting
Est. primary completion 2029-10-31 · NCT07193550 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1Uterine Cancer, Endometrial CancerRecruiting
Est. primary completion 2029-11-30 · NCT06795009 · CT.gov ↗
What to watch
2030 (5)
March 2030 (1)
Phase 1/2Germ Cell TumorRecruiting
Est. primary completion 2030-03 · NCT06937866 · CT.gov ↗
What to watch
April 2030 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2030-04-05 · NCT07750158 · CT.gov ↗
What to watch
May 2030 (1)
Phase 3Colorectal CancerEnrolling by invitation
Est. primary completion 2030-05-31 · NCT07620574 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2Anaplastic Thyroid CancerNot yet recruiting
Est. primary completion 2030-09-01 · NCT07470489 · CT.gov ↗
What to watch
November 2030 (1)
Phase 3Carcinoma, Renal CellRecruiting
Est. primary completion 2030-11-27 · NCT07489495 · CT.gov ↗
What to watch
2031 (3)
January 2031 (1)
Phase 2Pheochromocytoma, ParagangliomaNot yet recruiting
Est. primary completion 2031-01-01 · NCT07714551 · CT.gov ↗
What to watch
May 2031 (1)
Phase 1Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced LiposarcomaRecruiting
Est. primary completion 2031-05-31 · NCT06957431 · CT.gov ↗
What to watch
October 2031 (1)
Phase 1/2Renal Cell CarcinomaRecruiting
Est. primary completion 2031-10-26 · NCT07049926 · CT.gov ↗
What to watch
2032 (1)
February 2032 (1)
Phase 3Renal Cell CarcinomaRecruiting
Est. primary completion 2032-02-27 · NCT07227402 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 2High Grade Neuroendocrine NeoplasmsRecruiting
Est. primary completion 2034-12-31 · NCT06926634 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.